한글목차

세계의 카르바페넴계 항생제 시장의 미래는 병원 약국, 소매 약국, 온라인 약국의 각 시장에서의 기회로 유망시되고 있습니다. 세계의 카르바페넴계 항생제 시장은 2025-2031년에 CAGR 5.4%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 세균 감염률 증가와 수술 건수 증가입니다.

• Lucintel의 예측에 따르면 유형별로는 메로페넴이 예측 기간 중 가장 높은 성장세를 보일 것으로 예상됩니다.
• 유통채널별로는 병원약국이 가장 높은 성장이 예상됩니다.
• 지역별로는 의료 인프라가 잘 구축된 북미가 예측 기간 중 가장 높은 성장세를 보일 것으로 예상됩니다.

카바페넴계 항생제 시장의 전략적 성장 기회

카르바페넴계 항생제 시장은 세계 헬스케어 환경이 항생제 내성 감염의 위협에 대응하기 위해 지속적으로 성장하고 있는 가운데 성장세를 보이고 있습니다. 이러한 우려 증가는 제약업계의 이해관계자들에게 다양한 전략적 기회를 제공합니다. 연구 진전을 활용하고, 규제 프레임워크를 개선하고, 협력 관계를 촉진함으로써 기업은 이 중요한 시장을 활용할 수 있습니다. 이러한 기회를 식별하고 추구하는 것은 내성 패턴이 진화하는 가운데 혁신적인 치료법을 개발하고 환자 결과를 개선하는 데 필수적입니다.

• 신규 항생제 개발 : 내성균이 증가함에 따라 신규 카르바페넴계 항생제 개발이 시급한 상황입니다. 제약회사는 신규 화합물 창출 및 기존 화합물 개선에 연구개발 노력을 집중하여 미충족 의료 수요를 충족시키고 시장에서의 입지를 확대할 수 있습니다.
• 신흥 시장 진출 : 신흥 시장의 의료 인프라가 구축됨에 따라 효과적인 항생제 치료에 대한 수요가 증가하고 있습니다. 기업은 이러한 지역에서 사업 기회를 모색하고 현지 파트너십을 구축하여 판매 채널을 확장함으로써 다제내성 감염증의 확산에 대응할 수 있습니다.
• 병용요법에 대한 투자 : 카바페넴을 다른 항생제 및 보조제와의 병용요법에 대한 전략적 투자는 복잡한 감염에 대한 새로운 치료 옵션을 창출할 수 있습니다. 이러한 접근법은 효능을 향상시킬 뿐만 아니라 내성균의 발생을 지연시켜 시장에서의 경쟁 우위를 확보할 수 있습니다.
• 맞춤의료에 대한 관심 : 맞춤의료로의 전환은 카르바페넴 시장에 큰 성장 기회를 가져다 줄 것입니다. 유전자 및 미생물학적 프로파일에 기반한 표적 치료제의 개발은 치료 효과와 환자 결과를 개선하고, 혁신적인 항생제 솔루션의 선두주자로 자리매김할 수 있습니다.
• 항균제 관리 프로그램 강화 : 의료 기관과 협력하여 항균제 스튜어드십을 촉진함으로써 카르바페넴계 항생제의 책임감 있는 사용을 강화할 수 있으며, 세계 보건 구상과 협력하여 환자 예후를 개선하고, 내성균을 감소시키며, 지속가능한 관행이 점점 더 중요해지는 시장에서 브랜드 평판을 높일 수 있습니다. 지속가능한 관행이 점점 더 중요시되는 시장에서 브랜드 평판을 높일 수 있습니다.

카르바페넴계 항생제 시장은 전 세계가 항생제 내성 문제를 해결하기 위해 노력하고 있는 가운데 몇 가지 전략적 성장 기회를 제공합니다. 새로운 항생제 개발, 신흥 시장 진출, 병용요법에 대한 투자, 맞춤의료 수용, 항균제 스튜어드십 프로그램 지원 등을 통해 기업은 성공의 발판을 마련할 수 있습니다. 이러한 기회를 포착하는 것은 치료 옵션을 늘리고 내성균 퇴치를 위한 건강 결과를 개선하는 데 있으며, 매우 중요합니다.

카바페넴계 항생제 시장 성장 촉진요인 및 과제

카르바페넴계 항생제 시장은 항생제 내성 문제를 해결해야 할 시급한 필요성에 힘입어 빠르게 성장하고 있습니다. 다제내성균에 의한 감염이 증가함에 따라 효과적인 카바페넴계 치료제에 대한 수요는 그 어느 때보다 높아지고 있습니다. 그러나 시장은 성장과 혁신을 가로막는 심각한 문제에 직면해 있습니다. 이러한 촉진요인과 과제를 이해하는 것은 이 복잡한 상황을 극복하고 내성 감염과의 싸움에서 영향력을 강화하기 위한 전략을 수립하고자 하는 이해관계자들에게 필수적입니다.

카르바페넴계 항생제 시장을 촉진하는 요인은 다음과 같습니다. :

• 항생제 내성 증가 : 항생제 내성 증가는 카르바페넴계 항생제 시장의 주요 촉진요인입니다. 박테리아가 진화하고 기존 치료법에 대한 내성이 생겨나면서 의료진은 최후의 보루로 카르바페넴계 항생제에 의존하고 있으며, 이러한 심각한 감염에 대처할 수 있는 새롭고 효과적인 대안에 대한 수요가 증가하고 있습니다.
• R&D 투자 확대 : 신규 카바페넴계 항생제 연구개발에 대한 제약사들의 투자가 급증하고 있습니다. 이러한 추세는 항생제 내성 위기를 해결하고, 기술 혁신을 촉진하며, 보다 다양하고 효과적인 치료법 파이프라인을 구축하기 위한 공중보건 노력에 힘입어 더욱 가속화되고 있습니다.
• 규제 당국의 지원 강화 : 규제 당국은 새로운 항생제, 특히 내성균에 대한 항생제 승인에 우선순위를 두고 있습니다. 카르바페넴 계열 약물의 승인 절차를 가속화하는 구상은 제조업체가 제품을 더 빨리 시장에 출시할 수 있는 환경을 제공하여 이 분야의 성장을 가속할 수 있습니다.
• 헬스케어에 대한 인식 증가 : 항생제 내성에 대한 의료진과 환자들의 인식이 높아짐에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다. 이 문제에 대한 이해를 높이기 위한 교육적 구상과 캠페인은 카르바페넴계 항생제의 개발과 적절한 사용의 중요성에 더 많은 초점을 맞추는 데 기여하고 있습니다.
• 신흥 시장에서의 확장 : 신흥 시장에서는 의료 시스템의 발전과 함께 효과적인 항생제 치료에 대한 수요가 증가하고 있습니다. 의료 접근성이 개선되고 감염성 질환의 부담이 증가함에 따라 카르바페넴계 항생제 시장의 성장 기회가 커지면서 기업은 해당 지역에서의 사업 확장 및 제품 제공을 확대하고 있습니다.

카르바페넴계 항생제 시장이 해결해야 할 과제는 다음과 같습니다. :

• 높은 개발 비용 : 카르바페넴 시장의 중요한 과제 중 하나는 신규 항생제 개발에 따른 높은 비용입니다. 항생제 개발의 복잡한 특성과 엄격한 규제 요건이 결합되어 투자를 억제하고 혁신적인 치료법 시장 출시를 지연시킬 수 있습니다.

짧은 시장 독점 기간 : 신약 항생제의 독점 판매 기간이 제한적이라는 것은 제약기업에게 어려운 문제입니다. 특허가 비교적 빨리 만료되고 제네릭 의약품이 빠르게 등장함에 따라 기업은 R&D 투자 회수에 어려움을 겪을 수 있으며, 이는 장기적인 수익성 및 기술 혁신에 대한 인센티브에 영향을 미칠 수 있습니다.

• 규제 당국의 감시 강화 : 항생제 사용 및 승인에 대한 규제 당국의 감시가 강화되는 것은 제조업체에게 도전이 될 수 있습니다. 기업은 엄격한 규정 준수 요건을 충족하고 제품의 효과와 안전성을 입증해야 하므로 개발 프로세스가 지연되고 시장 개발이 지연될 수 있습니다.

카르바페넴계 항생제 시장은 항생제 내성 증가, R&D 투자 증가, 규제 당국의 지원 강화, 헬스케어에 대한 인식 증가, 신흥 시장에서의 확대 등의 주요 요인에 의해 주도되고 있습니다. 그러나 높은 개발 비용, 짧은 시장 독점 기간, 규제 당국의 강화된 감시와 같은 과제도 여전히 남아있습니다. 항생제 내성 감염과의 지속적인 싸움에서 혁신적이고 효과적인 솔루션을 제공하고자 하는 이해관계자들에게는 이러한 촉진요인과 과제를 해결하는 것이 매우 중요합니다.

목차

제1장 개요

제2장 세계의 카르바페넴계 항생제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 카르바페넴계 항생제 시장 동향(2019-2024년)과 예측(2025-2031년)
• 유형별 : 세계의 카르바페넴계 항생제 시장
  • Meropenem
  • Imipenem
  • Doripenem
  • Tebipenem
  • 기타
• 적응증별 : 세계의 카르바페넴계 항생제 시장
  • 복강내 감염증
  • 요로감염증
  • 폐렴
  • 세균성 수막염
  • 피부 및 피부 구조 감염증
  • 급성 골반 감염증
  • 기타
• 유통 채널별 : 세계의 카르바페넴계 항생제 시장
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제4장 2019-2031년 지역별 시장 동향과 예측 분석

• 지역별 : 세계의 카르바페넴계 항생제 시장
• 북미의 카르바페넴계 항생제 시장
• 유럽의 카르바페넴계 항생제 시장
• 아시아태평양지역카르바페넴계 항생제 시장
• 기타 지역의 카르바페넴계 항생제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별 : 세계의 카르바페넴계 항생제 시장의 성장 기회
  • 적응증별 : 세계의 카르바페넴계 항생제 시장의 성장 기회
  • 유통 채널별 : 카르바페넴계 항생제 시장의 성장 기회
  • 지역별 : 카르바페넴계 항생제 시장의 성장 기회
• 세계의 카르바페넴계 항생제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 카르바페넴계 항생제 시장의 생산능력 확대
  • 세계의 카르바페넴계 항생제 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 기업 개요

• Pfizer
• Merck
• Saint-Gobain
• Fresenius Kabi
• GlaxoSmithKline
• Eli Lilly and Company
• Teva Pharmaceutical Industries
• AstraZeneca
• Meiji Holdings
• Sandoz International

영문목차

The future of the global carbapenem-based antibiotic market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global carbapenem-based antibiotic market is expected to grow with a CAGR of 5.4% from 2025 to 2031. The major drivers for this market are the rising rates of bacterial infections and the increasing quantity of surgical procedures carried out.

• Lucintel forecasts that, within the type category, meropenem is expected to witness the highest growth over the forecast period.
• Within the distribution channel category, hospital pharmacy is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the presence of well-established healthcare infrastructure in this region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is evolving rapidly as the global healthcare landscape confronts the urgent challenge of antibiotic resistance. With rising cases of multidrug-resistant infections, there is a renewed focus on developing effective therapies. Innovations in research, changes in regulatory frameworks, and increased investment from both public and private sectors are shaping the market. As we delve into this dynamic environment, several emerging trends are reshaping the landscape for carbapenem antibiotics.

• Increased Research and Development: Pharmaceutical companies are investing heavily in R&D to discover novel carbapenem antibiotics and enhance existing formulations. This trend is driven by the pressing need to address resistant pathogens, leading to collaborations between academia and industry, ultimately fostering innovation and accelerating drug development timelines.
• Regulatory Support and Streamlined Approvals: Regulatory agencies are responding to the antibiotic crisis by expediting approval processes for new carbapenem drugs. Initiatives like the FDA's Qualified Infectious Disease Product (QIDP) designation are designed to incentivize the development of critically needed antibiotics, allowing for faster market entry and enhanced financial support for manufacturers.
• Focus on Combination Therapies: There is a growing trend toward developing combination therapies that include carbapenems alongside other antibiotics or adjuvants. This approach aims to enhance efficacy against resistant strains, reduce the likelihood of resistance development, and provide clinicians with more effective treatment options for complex infections.
• Rise of Personalized Medicine: The movement toward personalized medicine is influencing the carbapenem market as genomic technologies advance. Tailoring antibiotic treatments based on individual patient profiles and microbial resistance patterns promises to improve treatment outcomes and minimize side effects, making it a key focus for future developments.
• Expansion in Emerging Markets: Emerging markets, particularly in Asia and Africa, are witnessing increased demand for carbapenem antibiotics. Economic growth and rising healthcare access are contributing to this trend, prompting pharmaceutical companies to expand their portfolios and distribution networks to meet the needs of these rapidly evolving markets.

The carbapenem-based antibiotic market is poised for significant transformation as it adapts to the challenges posed by antibiotic resistance. Emerging trends such as increased R&D, regulatory support, combination therapies, personalized medicine, and market expansion highlight the ongoing commitment to developing effective solutions. These advancements are essential in the ultimate fight against resistant infections, ensuring better health outcomes for patients globally.

Recent Developments in the Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is rapidly evolving in response to the global challenge of antibiotic resistance. With rising infection rates caused by multidrug-resistant pathogens, the demand for effective carbapenem therapies is increasing. Recent advancements in research, regulatory frameworks, and collaborative efforts among stakeholders are reshaping this critical market segment. As healthcare systems work to combat the threat of resistant infections, several noteworthy developments have emerged, highlighting the proactive measures being taken to enhance the availability and efficacy of carbapenem antibiotics.

• New Drug Approvals: Recent months have seen several new carbapenem antibiotics receiving regulatory approval, aimed specifically at treating multidrug-resistant infections. These approvals are crucial as they expand the therapeutic arsenal available to clinicians, offering hope for better patient outcomes and demonstrating a commitment to addressing the antibiotic resistance crisis.
• Enhanced Formulations: Pharmaceutical companies are developing improved formulations of existing carbapenem antibiotics to enhance stability and bioavailability. These advancements aim to optimize dosing regimens, reduce side effects, and increase the overall efficacy of treatments, thereby providing healthcare providers with more effective options for managing severe infections.
• Focus on Combination Therapies: There is a growing emphasis on combination therapies involving carbapenems alongside other antibiotics or adjuncts. This approach aims to enhance the overall effectiveness of treatment regimens against resistant bacterial strains, reduce the risk of resistance development, and provide more comprehensive care for patients facing complex infections.
• Increased Investment in R&D: Significant investment in research and development is being observed as pharmaceutical companies and research institutions collaborate to innovate new carbapenem antibiotics. This trend is critical for addressing the urgent need for novel therapies, reflecting a proactive approach to tackling the evolving landscape of antibiotic resistance.
• Global Partnerships and Collaborations: There is a notable increase in global partnerships between pharmaceutical companies, research institutions, and governmental agencies. These collaborations focus on sharing knowledge, resources, and technologies to accelerate the development and distribution of effective carbapenem antibiotics, particularly in regions most affected by antibiotic resistance.

The carbapenem-based antibiotic market is undergoing significant changes driven by the pressing need to combat antibiotic resistance. Recent developments, including new drug approvals, enhanced formulations, combination therapies, increased R&D investments, and global partnerships, showcase a proactive response from the healthcare community. These advancements are vital in ensuring the availability of effective treatments for patients and addressing the ongoing challenges posed by resistant infections.

Strategic Growth Opportunities for Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is poised for growth as the global healthcare landscape continues to grapple with the rising threat of antibiotic-resistant infections. This growing concern presents a range of strategic opportunities for stakeholders in the pharmaceutical industry. By leveraging advancements in research, improving regulatory frameworks, and fostering collaborations, companies can position themselves to capitalize on this critical market. Identifying and pursuing these opportunities will be essential for developing innovative therapies and improving patient outcomes in the face of evolving resistance patterns.

• Development of Novel Antibiotics: There is a pressing need for the development of novel carbapenem antibiotics to combat increasingly resistant bacterial strains. Pharmaceutical companies can focus their R&D efforts on creating new compounds or improving existing ones, tapping into unmet medical needs and expanding their market presence.
• Expansion into Emerging Markets: As healthcare infrastructure improves in emerging markets, there is an increasing demand for effective antibiotic therapies. Companies can explore opportunities in these regions, establishing local partnerships and expanding distribution channels to address the rising prevalence of multidrug-resistant infections.
• Investment in Combination Therapies: Strategic investment in combination therapies that pair carbapenems with other antibiotics or adjuvants can create new treatment options for complex infections. This approach not only enhances efficacy but also helps in delaying the development of resistance, presenting a competitive advantage in the market.
• Focus on Personalized Medicine: The shift toward personalized medicine offers a significant growth opportunity for the carbapenem market. Developing targeted therapies based on genetic and microbiological profiles can improve treatment efficacy and patient outcomes, positioning companies as leaders in innovative antibiotic solutions.
• Strengthening Antimicrobial Stewardship Programs: Collaborating with healthcare institutions to promote antimicrobial stewardship can enhance the responsible use of carbapenem antibiotics. By aligning with global health initiatives, companies can improve patient outcomes, reduce resistance, and strengthen their brand reputation in a market increasingly focused on sustainable practices.

The carbapenem-based antibiotic market presents several strategic growth opportunities as the world confronts the challenges of antibiotic resistance. By focusing on the development of novel antibiotics, expanding into emerging markets, investing in combination therapies, embracing personalized medicine, and supporting antimicrobial stewardship programs, companies can position themselves for success. Seizing these opportunities will be crucial for enhancing treatment options and improving health outcomes in the fight against resistant infections.

Carbapenem-Based Antibiotic Market Driver and Challenges

The carbapenem-based antibiotic market is rapidly evolving, driven by the urgent need to address the global challenge of antibiotic resistance. As infections caused by multidrug-resistant bacteria rise, the demand for effective carbapenem therapies is more critical than ever. However, the market also faces significant challenges that could hinder growth and innovation. Understanding these drivers and challenges is essential for stakeholders looking to navigate this complex landscape and develop strategies to enhance their impact in the fight against resistant infections.

The factors responsible for driving the carbapenem-based antibiotic market include:

• Increasing Antibiotic Resistance: The escalating prevalence of antibiotic-resistant infections is a primary driver for the carbapenem market. As bacteria evolve and become resistant to existing treatments, healthcare providers are increasingly relying on carbapenems as a last line of defense, driving demand for new and effective options to combat these serious infections.
• Growing Investment in R&D: There is a noticeable surge in investment from pharmaceutical companies focusing on research and development of new carbapenem antibiotics. This trend is fueled by public health initiatives aimed at addressing the antibiotic resistance crisis, encouraging innovation, and creating a more diverse pipeline of effective treatments.
• Enhanced Regulatory Support: Regulatory agencies are increasingly prioritizing the approval of new antibiotics, particularly those targeting resistant infections. Initiatives that expedite the approval process for carbapenem drugs provide manufacturers with a conducive environment to bring their products to market more quickly, fostering growth in the sector.
• Rising Healthcare Awareness: Increased awareness among healthcare providers and patients about antibiotic resistance is driving demand for effective treatments. Educational initiatives and campaigns aimed at promoting understanding of this issue contribute to a greater focus on the importance of developing and utilizing carbapenem antibiotics appropriately.
• Expansion in Emerging Markets: Emerging markets are witnessing a rise in demand for effective antibiotic therapies as healthcare systems develop. Improved access to healthcare and the rising burden of infections present significant opportunities for growth in the carbapenem market, encouraging companies to expand their reach and product offerings in these regions.

Challenges in the carbapenem-based antibiotic market are:

• High Development Costs: One of the significant challenges in the carbapenem market is the high cost associated with developing new antibiotics. The complex nature of antibiotic development, coupled with stringent regulatory requirements, can deter investment and slow the introduction of innovative therapies to the market.

Short Market Exclusivity: The limited exclusivity period for new antibiotics poses a challenge for pharmaceutical companies. With patents expiring relatively quickly and the rapid emergence of generics, companies may struggle to recoup their investment in research and development, impacting long-term profitability and innovation incentives.

• Growing Regulatory Scrutiny: Increasing scrutiny from regulatory bodies regarding antibiotic usage and approval can present challenges for manufacturers. Companies must navigate stringent compliance requirements and demonstrate the effectiveness and safety of their products, which can slow down the development process and hinder market entry.

The carbapenem-based antibiotic market is driven by significant factors such as rising antibiotic resistance, increased investment in R&D, enhanced regulatory support, growing healthcare awareness, and expansion in emerging markets. However, challenges including high development costs, short market exclusivity, and growing regulatory scrutiny remain prevalent. Addressing these drivers and challenges will be crucial for stakeholders aiming to innovate and provide effective solutions in the ongoing battle against antibiotic-resistant infections.

List of Carbapenem-Based Antibiotic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies carbapenem-based antibiotic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the carbapenem-based antibiotic companies profiled in this report include-

• Pfizer
• Merck
• Saint-Gobain
• Fresenius Kabi
• GlaxoSmithKline
• Eli Lilly and Company
• Teva Pharmaceutical Industries
• AstraZeneca
• Meiji Holdings
• Sandoz International

Carbapenem-Based Antibiotic by Segment

The study includes a forecast for the global carbapenem-based antibiotic market by type, indication, distribution channel, and region.

Carbapenem-Based Antibiotic Market by Type [Analysis by Value from 2019 to 2031]:

• Meropenem
• Imipenem
• Doripenem
• Tebipenem
• Others

Carbapenem-Based Antibiotic Market by Indication [Analysis by Value from 2019 to 2031]:

• Intra-Abdominal Infections
• Urinary Tract Infections
• Pneumonia
• Bacterial Meningitis
• Skin & Skin Structure Infections
• Acute Pelvic Infections
• Others

Carbapenem-Based Antibiotic Market by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Carbapenem-Based Antibiotic Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Carbapenem-Based Antibiotic Market

The carbapenem-based antibiotic market is experiencing significant transformations due to rising antibiotic resistance, increased regulatory scrutiny, and the need for innovative therapies. As healthcare systems grapple with multidrug-resistant infections, countries like the United States, China, Germany, India, and Japan are focusing on enhancing their antibiotic development pipelines and improving access to effective treatments. Recent advancements include novel formulations, regulatory approvals, and strategic collaborations aimed at combating the growing threat of resistant pathogens.

• United States: The U.S. has seen a surge in research and development for new carbapenem formulations, with several companies receiving FDA approvals for innovative drugs that target resistant infections. Increased funding for antibiotic development and initiatives like the PASTEUR Act aims to incentivize manufacturers, fostering a more robust market landscape.
• China: China is witnessing rapid growth in its carbapenem market, driven by escalating rates of antibiotic resistance. The government is prioritizing antibiotic stewardship programs and investing in local pharmaceutical companies to develop novel carbapenem agents, leading to a rise in production capacity and improved regulatory frameworks.
• Germany: Germany is focusing on enhancing its antimicrobial stewardship programs to combat resistance. Recent collaborations between pharmaceutical firms and research institutions have led to the development of new carbapenem products. Regulatory bodies are streamlining approval processes, making it easier to bring innovative antibiotics to market.
• India: The Indian market is seeing significant advancements in the production of generic carbapenem antibiotics, driven by high demand due to resistant infections. Initiatives aimed at improving manufacturing standards and regulatory compliance are enhancing product quality, while government programs are promoting research into novel antibiotic solutions.
• Japan: Japan is actively addressing the challenge of antibiotic resistance through increased investment in research and development. Recent approvals for new carbapenem antibiotics are coupled with a push for international collaboration in drug development. The government is also emphasizing the importance of antibiotic stewardship to reduce overuse and misuse.

Features of the Global Carbapenem-Based Antibiotic Market

Market Size Estimates: Carbapenem-based antibiotic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Carbapenem-based antibiotic market size by type, indication, distribution channel, and region in terms of value ($B).

Regional Analysis: Carbapenem-based antibiotic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, indication, distribution channel, and regions for the carbapenem-based antibiotic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the carbapenem-based antibiotic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the carbapenem-based antibiotic market by type (meropenem, imipenem, doripenem, tebipenem, and others), indication (intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin & skin structure infections, acute pelvic infections, and others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Carbapenem-Based Antibiotic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Carbapenem-Based Antibiotic Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Carbapenem-Based Antibiotic Market by Type
  • 3.3.1: Meropenem
  • 3.3.2: Imipenem
  • 3.3.3: Doripenem
  • 3.3.4: Tebipenem
  • 3.3.5: Others
• 3.4: Global Carbapenem-Based Antibiotic Market by Indication
  • 3.4.1: Intra-Abdominal Infections
  • 3.4.2: Urinary Tract Infections
  • 3.4.3: Pneumonia
  • 3.4.4: Bacterial Meningitis
  • 3.4.5: Skin & Skin Structure Infections
  • 3.4.6: Acute Pelvic Infections
  • 3.4.7: Others
• 3.5: Global Carbapenem-Based Antibiotic Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Carbapenem-Based Antibiotic Market by Region
• 4.2: North American Carbapenem-Based Antibiotic Market
  • 4.2.1: North American Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.2.2: North American Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.3: European Carbapenem-Based Antibiotic Market
  • 4.3.1: European Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.3.2: European Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.4: APAC Carbapenem-Based Antibiotic Market
  • 4.4.1: APAC Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.4.2: APAC Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
• 4.5: ROW Carbapenem-Based Antibiotic Market
  • 4.5.1: ROW Market by Type: Meropenem, Imipenem, Doripenem, Tebipenem, and Others
  • 4.5.2: ROW Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Type
  • 6.1.2: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Indication
  • 6.1.3: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Carbapenem-Based Antibiotic Market by Region
• 6.2: Emerging Trends in the Global Carbapenem-Based Antibiotic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Carbapenem-Based Antibiotic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Carbapenem-Based Antibiotic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Merck
• 7.3: Saint-Gobain
• 7.4: Fresenius Kabi
• 7.5: GlaxoSmithKline
• 7.6: Eli Lilly and Company
• 7.7: Teva Pharmaceutical Industries
• 7.8: AstraZeneca
• 7.9: Meiji Holdings
• 7.10: Sandoz International